Latest news with #ThomasGallagher
Glasgow Times
5 days ago
- Glasgow Times
Clydebank man possessing knife was wearing body armour
Thomas Gallagher was drinking in the company of a pregnant woman at a property in Second Avenue when he started calling her "the devil". The 39-year-old was shouting and acting aggressively. The woman was distressed and left while barefoot, Dumbarton Sheriff Court was told. A witness saw her and could hear her crying. Another neighbour heard Gallagher threatening to "murder" her and "I hope you die". Around 1.10am, police arrived. The man answered the door, intoxicated, and started threatening officers. He was repeatedly reminded they were there to check on the welfare of everyone there. READ MORE: Drug dealer caught as phone lights up with WhatsApp texts during police search Fiscal depute Euan Nicholson said the man continued to threaten to fight officers and "said he had body armour". As additional police arrived, he then opened his tracksuit top and showed his armour and a knife in the front pouch. Gallagher, listed in court papers as a prisoner at Low Moss, also had a knuckleduster in his right trouser pocket. Police had to deploy PAVA spray to his face. He pleaded guilty in June to shouting, swearing, uttering threats and making derogatory remarks towards his partner at a property on February 8 this year. It was aggravated by being against a partner or ex. He further shouted, swore and uttered threats of violence and made homophobic remarks to two police officers. This was aggravated by prejudice relating to sexual orientation. And he admitted having a knife and having a knuckleduster. READ MORE: Former cop caught driving while disqualified after crash The Crown accepted last month that he did not shoot a crossbow at a veranda door at Orbiston Place on May 18 and 19, 2024. At sentencing on July 8, his defence solicitor said it was an "extremely frightening incident". "He is apologetic about his behaviour on the night in question," he said. There was not just alcohol in his client's system, but a "cocktail" that "acted as a catalyst for his behaviour". He accepted Gallagher had a lengthy record, including for past offences of violence. But he said the last one was 10 years ago. Because he had been locked up for about five months, under automatic early release, that was a 10-month sentence, explained the solicitor. Sheriff Robert Carr said: "This was an incident involving appalling behaviour on your partner. "You have a bad record. There is no alternative to a custodial sentence." He jailed Gallagher for 10 months, backdated to February 10.
Daily Mail
07-07-2025
- Entertainment
- Daily Mail
Liam and Noel Gallagher's estranged father Tommy lashes out at Oasis stars in foul-mouthed rant
The estranged father of Liam and Noel Gallagher has hit out at his sons by saying they 'don't know f***ing music'. Irish-born Thomas Augustin Gallagher hasn't seen the Oasis duo for years, who've never forgiven him for how they treated their mother Peggy when they were boys. Since the duo reunited for their tour last week, a video has come to light of Thomas - who goes by Tommy - dismissing his sons' illustrious career. In the 2018 video, TikToker Jack Burke was filming in Manchester when Tommy walked past and intervened, saying: 'Have you heard of the band Oasis? I'm their father. Noel and Liam Gallagher.' When Jack asked for his name, he said: 'Thomas Augustus Gallagher' - pulling his passport out of his pocket to show to Jack. As Jack walks off, Tommy retorts: '[Them] guys talking about music, they wouldn't f***ing know music if it f***ing bit them.' In the comments section of the video, one follower claimed that Tommy is a regular where she works and often boasts about being their father. She claimed: 'He always comes in the pub I work in telling us all.' MailOnline has contacted Liam and Noel's representatives for comment. Tommy and Peggy divorced in 1986 after being separated for a number of years, with Peggy moving out of their family home in Burnage with their sons after Tommy's drinking and gambling problem spiralled into violent outbursts. Noel was 19 and Liam 14 at the time. Speaking about the split, Peggy previously said: 'I left him a knife and a fork and a spoon. And I think I left him too much.' Noel and Liam cut ties with their father when they moved out, with Liam opening about his childhood in a 2018 interview with The Telegraph. He said: 'I was about seven when my mam left my dad. He was out all the time, fighting, beating my mam up, beating Noel and Paul up. Never touched me, though. 'Then, one night, while he was out, my mam got her brothers round, got all our gear in a truck, left him a mattress, and we went off to our new house.' Meanwhile, Noel confessed the abuse he suffered at the hands of his 'violent, alcoholic' father made him worry about what sort of parent he would be. Speaking on Radio 4's Desert Island Discs in 2015, he revealed he developed a stammer as a result of the beatings he got from his father, and said he didn't want to repeat the mistakes which scarred his 'horrific' childhood. Tommy last made headlines in 2021 when he urged his sons to buy their three-bed childhood home to save him from homelessness. He'd lived there since 1972. He faced having his house repossessed when his mortgage deal expired, leaving him needing to cough up £27,000. He claimed a childhood pal of Noel's called Thomas Keenan suggested his brother Ricky could buy the house for him, and it was agreed he could live in the home rent-free. However it is alleged he actually signed papers agreeing to pay £650 a month in rent. The house is now owned by a property firm and neighbours say they haven't seen Tommy in a while. Last week saw Liam and Noel reunite for the first time in 16 years as they kicked off their tour in Cardiff on Friday. Fans of the band were blown away as the duo delivered an electrifying set, packed with energy and nostalgia. Throughout their various sets, poignant pictures of the family's home in Manchester flashed up on the screen along with baby pictures of both brothers. Old black and white pictures of their mum Peggy and dad Tommy were also flashed in the screen from time to time as Stand By Me played. On Saturday night, Noel and Liam continued their display of unity as they held hands during their entrance. While the pair had chemistry on stage, it's been said Liam and Noel are taking extreme measures throughout their reunion tour by staying apart to avoid another rift. It's claimed they are staying in separate hotels half an hour away from each other.
Yahoo
18-06-2025
- Business
- Yahoo
Alpha Modus Expands CashX Rollout via Strategic U.S. Reseller Agreement with Genmega
CORNELIUS, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings Inc. (NASDAQ: AMOD), an emerging leader in AI-powered retail innovation, today announced it has entered into a formal U.S. reseller agreement with Genmega, Inc., a leading manufacturer of self-service kiosks and ATMs. This strategic relationship significantly expands the reach of Alpha Modus' rollout of the CashX platform, positioning the Company for accelerated national deployment of next-generation consumer engagement and payment kiosks."This agreement with Genmega unlocks scale," said William Alessi, CEO of Alpha Modus. "It allows us to accelerate CashX deployments through an experienced partner trusted by major financial networks and national retailers. This step validates our vision of powering the intersection of AI, retail media, and financial inclusion through real-time digital infrastructure." As part of the Alpha Modus ecosystem, Genmega will offer cutting-edge AI-enabled kiosk solutions that deliver tailored advertising, bill payment, money transfer, online shopping, mobile top up and check cashing services, with the ability to bridge into inventory alerts, smart planograms, and anti-shrinkage tools for the retailers—all core features of Alpha Modus' IP portfolio. Genmega's wide footprint and integration capability is expected to streamline installations and support across the U.S., helping fast-track Alpha Modus' efforts to capture a growing share of the retail media and self-service terminal market. According to eMarketer and Insider Intelligence, U.S. retail media ad spend is projected to exceed $60 billion in 2025, with further growth driven by AI-powered personalization and in-store activation. At the same time, the global self-service kiosk market is valued at $28–36 billion this year, expected to double by patented technology at the convergence of these trends, Alpha Modus is uniquely positioned to capture recurring revenue from kiosk deployment, data monetization, and digital advertising. The partnership with Genmega enhances the Company's ability to scale rapidly through established distribution, supporting Alpha Modus' long-term vision to become a category-defining platform in AI retail infrastructure. Thomas Gallagher, Alpha Modus Chief Revenue Officer, commented:"Our partnership with Genmega marks a pivotal milestone in our rollout strategy. This isn't just about hardware—it's about harnessing AI at the edge to unlock deeper value for retailers and consumers. We are executing with purpose, and this alliance ensures our infrastructure can scale in lockstep with demand." This announcement follows Alpha Modus' recent patent licensing agreement with VSBLTY (OTC: VSBLT), further strengthening the Company's expanding partner ecosystem and reinforcing its leadership in AI-driven retail transformation. About Alpha Modus Holdings Modus (NASDAQ: AMOD) develops and licenses patented AI-driven retail technologies designed to optimize in-store engagement, drive revenue through intelligent media, and empower brands and retailers with actionable consumer insights. From smart kiosks to predictive inventory and retail media networks, Alpha Modus is shaping the next frontier of data-powered more information, visit For more information and to access Alpha Modus' press room, visit: Forward-Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Alpha Modus's actual results may differ from their expectations, estimates, and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Alpha Modus's expectations with respect to future performance. Alpha Modus cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Alpha Modus does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. Contact Information Investor RelationsAlpha Modus Holdings, ir@ Follow us on LinkedIn | Follow us on X A photo accompanying this announcement is available at
Yahoo
03-06-2025
- Business
- Yahoo
Genprex to Participate at BIO 2025 International Convention
AUSTIN, Texas, June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2025 International Convention taking place June 16-19, 2025 in Boston, Mass. In attendance from Genprex's executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. Throughout the duration of the conference, Mr. Gallagher will be available in-person to conduct one-on-one meetings with industry groups to provide an overview of the Company's gene therapies for cancer and diabetes. For those interested in meeting with Mr. Gallagher or other members of Genprex's management team, please request a meeting through the conference meeting portal or by contacting Investor Relations at investors@ The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. About Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn. Cautionary Language Concerning Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc.(877) 774-GNPX (4679) GNPX Investor Relationsinvestors@ GNPX Media ContactKalyn Dabbsmedia@ View original content to download multimedia: SOURCE Genprex, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
04-03-2025
- Business
- Associated Press
Genprex to Participate at BIO Europe Spring 2025
AUSTIN, Texas, March 4, 2025 /PRNewswire/ -- Genprex, Inc. ('Genprex' or the 'Company') (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 17-19, 2025 in Milan, Italy. In attendance will be Ryan Confer, President and Chief Executive Officer and Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. Throughout the duration of the conference, Genprex executives will be available to conduct one-on-one meetings with industry groups to provide an overview of the Company's gene therapies for cancer and diabetes. For those interested in meeting with Genprex management during the conference, please request a meeting through the conference meeting portal or by contacting Investor Relations at [email protected]. The event is expected to bring together more than 3,700 executives from biotech, pharma and finance companies to engage in more than 20,000 one-on-one meetings. About Genprex, Inc. Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn. Cautionary Language Concerning Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under 'Item 1A – Risk Factors' in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals, the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc. Kalyn Dabbs
